drugset / Trial / NCT03834623
Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
Phase 2
Completed
23 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb · collabCelgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).
Timeline
- Start
- 2019-05-14
- Primary completion
- 2021-06-29
- Completion
- 2021-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avadomide | Other / unclassified | 2 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |